Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-04-15 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于公司2018年度现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2018年度现场检查报告" which translates to "2018 On-site Inspection Report" by China International Capital Corporation Limited regarding Betta Pharmaceuticals Co., Ltd. The content details a thorough inspection of corporate governance, internal controls, information disclosure, protection of company interests, use of raised funds, performance, and shareholder commitments for the fiscal year 2018. It includes detailed compliance checks, interviews, and verification of company practices. This is a standalone audit or inspection report focusing on regulatory compliance and internal controls rather than a full annual report or financial statement. It is not an announcement or a brief summary but a detailed report of an audit/inspection. Therefore, it fits best under the category Audit Report / Information (AR). The document length (4695 characters) is sufficient to contain substantive content, not just an announcement or certification. Hence, the classification is AR with high confidence. FY 2018
2019-04-15 Chinese
募集资金年度存放与使用情况鉴证报告（2018年度）
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Deposit and Use of Raised Funds" for the year 2018. It is prepared by an accounting firm providing an assurance opinion on the company's special report about the deposit and actual use of raised funds. The document references regulatory guidelines related to the management and use of raised funds by listed companies, including specific Chinese regulatory notices and Shenzhen Stock Exchange rules. It contains detailed financial data on the raised funds, their storage, usage, changes in investment projects, and compliance with regulations. The document is a standalone audit/verification report focused on the raised funds usage and management, not a full annual report or interim report. It is not a mere announcement or certification but contains substantive financial and compliance information. Therefore, it fits the category of an Audit Report / Information (AR) which includes standalone audit reports and applied accounting principles related to specific regulatory requirements, excluding full annual reports. FY 2018
2019-04-15 Chinese
中国国际金融股份有限公司关于公司2018年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-evaluation report for the year 2018 of Betta Pharmaceuticals Co., Ltd., with verification opinions from China International Capital Corporation Limited as the sponsoring institution. It discusses the scope, standards, and results of internal control evaluations, including financial and non-financial control defects, governance structure, risk assessment, control activities, information communication, and internal supervision. The document is detailed and contains substantive content about internal control systems and their effectiveness, not merely an announcement or certification. It is not a full annual report (10-K) but a specialized report focusing on internal control evaluation and audit opinions related to internal controls. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. Therefore, the appropriate classification is AR with high confidence. FY 2018
2019-04-15 Chinese
2018年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (325 characters) titled as a '2018 Annual Report Disclosure Reminder Announcement' from the company. It states that the full 2018 Annual Report and summary were disclosed on April 16, 2019, on a regulatory website, and advises investors to review it. The document itself does not contain the full annual report or substantive financial data, but merely announces the availability of the report elsewhere. According to the MENU VS MEAL RULE, such a brief notice that points to the report's publication is classified as a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2019-04-15 Chinese
专项审计说明（2018年度）
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计说明" which translates to a "Special Audit Explanation" for the year 2018. It includes an auditor's report on the company's related party fund occupation situation, with detailed audit responsibilities, management responsibilities, and an audit opinion. The document is issued by a registered accounting firm and contains audit evidence and conclusions. It is not a full annual report but a standalone audit report focusing on a specific audit area (related party fund occupation). The document length is 2572 characters, which is relatively short but contains substantive audit content, not just an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR). FY 2018
2019-04-15 Chinese
2018年度独立董事述职报告（赵骏）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's 2018 Annual Report" for Betta Pharmaceuticals Co., Ltd. It details the independent director's duties, attendance at board meetings, opinions on various company proposals, committee work, investigations, investor protection efforts, and training during the year 2018. The content focuses on governance, board activities, and compliance rather than financial statements or audit results. It is a detailed report by an independent director on their role and activities over the year, which aligns with Board/Management Information filings. It is not an Annual Report (10-K), Audit Report, or any other financial or regulatory filing. The document length is about 4512 characters, which is substantive and not a mere announcement. Therefore, the best fitting category is Board/Management Information (MANG).
2019-04-15 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.